文献速递脑血管病

PCISOS风险分层区分轻型后循环缺血性卒中的异质性结局

PCISOS Risk Profiles Stratify Heterogeneous Outcomes in Minor Posterior Circulation Ischemic Stroke: A Post Hoc Analysis of the CHANCE-2 Trial.
PubMed 文献 · Stroke · 2025-09-10

基于CHANCE-2试验的事后分析纳入1379例携带CYP2C19功能缺失等位基因的轻型后循环缺血性卒中患者,按PCISOS分为低危(≤15)、中危(16-20)和高危(≥21)组。90天卒中复发率分别为6.0%、8.2%和18.5%(P<0.001),风险随分层递增,且替格瑞洛-阿司匹林在低、中危组降低mRS 1-6评分率,高危组未见获益(Pinteraction=0.03)。

要点

  • PCISOS低、中、高危组90天卒中复发率分别为6.0%、8.2%、18.5%。
  • 高危组(PCISOS≥21)复发风险显著升高,调整后HR为3.02(95%CI 1.52-6.02)。
  • 替格瑞洛-阿司匹林仅在低、中危组改善mRS 1-6结局,存在治疗与风险交互作用。

核心结论

  • PCISOS可在轻型后循环缺血性卒中中有效分层,识别结局风险异质及对替格瑞洛-阿司匹林反应不同的亚组。
  • PCISOS≥21为NIHSS定义轻型卒中内的高危亚组,未来试验可能需定制策略。
  • PCISOS≤15可能比NIHSS≤3更准确界定真正低危患者,提高试验效率。

研究设计与样本

  • CHANCE-2试验为多中心随机试验,入组携带CYP2C19功能缺失等位基因的轻型卒中或高危TIA患者,接受替格瑞洛-阿司匹林或氯吡格雷-阿司匹林治疗。
  • 本分析为事后分析,纳入1379例后循环缺血性卒中患者,按PCISOS分为低危(≤15)、中危(16-20)、高危(≥21)组。
  • 主要结局为90天卒中复发,采用Cox和logistic回归模型并校正基线不平衡协变量。

主要发现

  • 1379例患者中位年龄64.0(56.6-70.7)岁,男性占67.4%。
  • 90天卒中复发率低、中、高危组分别为6.0%、8.2%、18.5%(P<0.001)。
  • 复发风险递增:中危调整后HR 1.32(95%CI 0.87-2.02),高危3.02(95%CI 1.52-6.02),Ptrend=0.008。
  • mRS 2-6结局:中危调整后OR 2.21(95%CI 1.28-3.84),高危3.53(95%CI 1.42-8.74),Ptrend<0.001。
  • 替格瑞洛-阿司匹林降低低、中危组mRS 1-6评分率但不降低高危组(Pinteraction=0.03);PCISOS≤15者良好结局(mRS 0-1)较NIHSS≤3者更常见(P=0.02)。

关键数值与推荐

  • PCISOS分层阈值:低危≤15,中危16-20,高危≥21。
  • 主要结局90天卒中复发:低危6.0%、中危8.2%、高危18.5%(P<0.001)。
  • 高危组复发调整后HR 3.02(95%CI 1.52-6.02),Ptrend=0.008。
  • mRS 2-6:高危调整后OR 3.53(95%CI 1.42-8.74),Ptrend<0.001。
  • 治疗与风险交互作用Pinteraction=0.03;PCISOS≤15与NIHSS≤3良好结局比较P=0.02。

临床怎么用

  • 可用PCISOS对轻型后循环缺血性卒中患者进行90天复发风险分层,辅助识别高危人群。
  • 对PCISOS≥21的高危患者,替格瑞洛-阿司匹林未显示mRS 1-6获益,需考虑其他或定制策略。
  • PCISOS≤15或可替代NIHSS≤3用于筛选真正低危患者,提升临床试验效率。

局限性

  • 本研究为CHANCE-2试验的事后分析,结论需在前瞻性研究中验证。
  • 研究人群限于携带CYP2C19功能缺失等位基因的轻型卒中或高危TIA患者,外推需谨慎。
  • 高危亚组样本量有限,相关治疗交互作用有待进一步探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk stratification in posterior circulation ischemic stroke (PCIS) is challenging. Although the Posterior Circulation Ischemic Stroke Outcome Score (PCISOS) was developed to address this, its utility in minor PCIS and in identifying homogeneous populations for clinical trials or treatment-responsive subgroups remains uncertain. METHODS: CHANCE-2 (Ticagrelor or Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II) was a multicenter, randomized trial that enrolled patients with minor stroke or high-risk transient ischemic attack who carried CYP2C19 loss-of-function alleles. Patients received ticagrelor-aspirin or clopidogrel-aspirin. This secondary analysis included patients with PCIS, stratified into low- (≤15), intermediate- (16-20), and high-risk (≥21) groups based on PCISOS. The primary outcome was 90-day stroke recurrence. Outcomes were analyzed using Cox and logistic regression models, adjusting for significantly imbalanced baseline covariates relevant to each comparison. RESULTS: Among 1379 patients with PCIS (median age, 64.0 [56.6-70.7] years; 67.4% male), 90-day stroke recurrence occurred in 6.0%, 8.2%, and 18.5% of the low-, intermediate-, and high-risk PCISOS groups, respectively (P<0.001). Risk increased progressively (adjusted hazard ratio for intermediate-risk, 1.32 [95% CI, 0.87-2.02]; high-risk, 3.02 [95% CI, 1.52-6.02]; Ptrend=0.008). Similar associations were observed for modified Rankin Scale score of 2 to 6 outcomes (adjusted odds ratio for intermediate-risk, 2.21 [95% CI, 1.28-3.84]; high-risk, 3.53 [95% CI, 1.42-8.74]; Ptrend<0.001). A treatment-by-risk interaction was observed: ticagrelor-aspirin reduced the modified Rankin Scale score of 1 to 6 rates in low- and intermediate-risk patients, but not in high-risk patients (Pinteraction=0.03). Favorable outcome (modified Rankin Scale score of 0-1) was more common in patients with PCISOS ≤15 than in those with National Institutes of Health Stroke Scale score ≤3 (P=0.02). CONCLUSIONS: PCISOS provides effective risk stratification in minor PCIS, identifying subgroups with heterogeneous outcome risks and differential response to ticagrelor-aspirin. Patients with PCISOS ≥21, a high-risk subgroup within National Institutes of Health Stroke Scale-defined minor strokes, remain underexplored and may benefit from tailored strategies in future trials. A threshold of PCISOS ≤15 may more accurately define truly low-risk patients than National Institutes of Health Stroke Scale score ≤3, thereby improving trial efficiency and advancing precision in PCIS research. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04078737.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Lin X, Guo C, Meng X, et al. PCISOS Risk Profiles Stratify Heterogeneous Outcomes in Minor Posterior Circulation Ischemic Stroke: A Post Hoc Analysis of the CHANCE-2 Trial. Stroke. 2025. PMID: 40927840. doi:10.1161/STROKEAHA.125.053054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。